Loading...
Market
Rite Aid stock price up by 10% by July 31, 2024?
5
Resolution / Starting Odds
Yes • 50%
No • 50%
Stock market data from financial news platforms like Bloomberg or Reuters
Story
Rite Aid Wins $200 Million Dispute Over Elixir Sale After Judge's Monday Ruling
Jun 24, 2024, 06:00 PM
Rite Aid has successfully defeated MedImpact Healthcare Systems in a $200 million dispute over the sale of its pharmacy benefit manager, Elixir. A judge ruled on Monday that MedImpact is not entitled to recoup the $200 million in extra costs, as it assumed Elixir's debts when it acquired the company. This ruling absolves Rite Aid of any responsibility for the additional costs tied to the recent acquisition.
View original story
Similar markets
Net Profit • 25%
Net Loss < $100 Million • 25%
Net Loss $100-$500 Million • 25%
Net Loss > $500 Million • 25%
Increase by > 5% • 25%
Increase by ≤ 5% • 25%
Decrease by ≤ 5% • 25%
Decrease by > 5% • 25%
